Cart

YOUR CART IS EMPTY

Add research compounds to begin your order.

Human controlled primaryStrong for measured surrogate endpointCompleted; peer reviewed

SURPASS-2 active-comparator trial

TIRZEPATIDE-STUDY-P033

Frías et al. (2021), SURPASS-2.

Study design

Record details

Design: Randomized, open-label, active-comparator phase 3 trial.
Population or model: People with type 2 diabetes in the protocol-defined population.
Material tested: Lilly-manufactured tirzepatide clinical product.
Comparator: Semaglutide comparator used in the protocol.

Evidence record

Endpoints

Mean change in glycated hemoglobin (HbA1c) under the trial conditions.

Qualified findings

SURPASS-2 reported noninferiority and superiority for mean HbA1c change versus the protocol comparator.

Limitations

Open-label active comparison; comparator, endpoint, population, and prespecified analysis must remain attached. HbA1c is a surrogate endpoint.

Reports and sources

P033Human controlled primary, PEER REVIEWED; RESULTS POSTED

Frías et al. 2021 SURPASS-2

(2021). DOI: 10.1056/NEJMoa2107519